94 related articles for article (PubMed ID: 6097258)
21. SV40 tumor rejection induced by vesicular stomatitis virus bearing SV40 tumor-specific transplantation antigen (SV40-TSTA). I. Specificity of immunoprotection and effect of enzyme treatment on TSTA activity.
Ansel S; Huet C; Tournier P
Int J Cancer; 1977 Jul; 20(1):51-60. PubMed ID: 71274
[TBL] [Abstract][Full Text] [Related]
22. Activation of macrophages for cytolysis of virally infected cells by monoclonal antibody to the 73-kDa lipopolysaccharide receptor.
LeBlanc PA
J Leukoc Biol; 1994 Feb; 55(2):262-4. PubMed ID: 7507971
[TBL] [Abstract][Full Text] [Related]
23. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
24. Interaction with vesicular stomatitis virus-infected BALB/c3T3 cells inhibits the synthesis of nitric oxide in activated murine bone marrow culture-derived macrophages.
Crowder CW; Murphy WJ; Russell SW; LeBlanc PA
J Leukoc Biol; 1999 May; 65(5):605-13. PubMed ID: 10331488
[TBL] [Abstract][Full Text] [Related]
25. The relationship of decreased serum thyrotropin and increased colonic temperature in rats exposed to microwaves.
Lu ST; Lebda NA; Pettit S; Michaelson SM
Radiat Res; 1985 Dec; 104(3):365-86. PubMed ID: 4080981
[TBL] [Abstract][Full Text] [Related]
26. Genetically determined resistance to lethal vesicular stomatitis virus in syrian hamsters.
Fultz PN; Streilein JW; Shadduck JA; Kang CY
Adv Exp Med Biol; 1981; 134():339-51. PubMed ID: 6261542
[No Abstract] [Full Text] [Related]
27. Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus.
Ivec M; Botić T; Koren S; Jakobsen M; Weingartl H; Cencic A
Antiviral Res; 2007 Sep; 75(3):266-74. PubMed ID: 17512614
[TBL] [Abstract][Full Text] [Related]
28. In vitro induction of tumor-specific immunity by highly purified VSV grown in SV40-transformed cells and tumor glycolipids incorporated into liposomes.
Ansel S
Int J Cancer; 1983 Jun; 31(6):785-90. PubMed ID: 6190766
[TBL] [Abstract][Full Text] [Related]
29. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle.
Mackett M; Yilma T; Rose JK; Moss B
Science; 1985 Jan; 227(4685):433-5. PubMed ID: 2981435
[TBL] [Abstract][Full Text] [Related]
30. Peripheral T cells in mice lacking p56lck do not express significant antiviral effector functions.
Molina TJ; Bachmann MF; Kündig TM; Zinkernagel RM; Mak TW
J Immunol; 1993 Jul; 151(2):699-706. PubMed ID: 8393038
[TBL] [Abstract][Full Text] [Related]
31. Limitation of VSV infection by the host's response to VSV-associated cellular antigens.
Hecht TT; Paul WE
J Immunol; 1982 Oct; 129(4):1736-41. PubMed ID: 6180021
[TBL] [Abstract][Full Text] [Related]
32. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo.
Fernandez-Sesma A; Peluso RW; Bai X; Schulman JL; Levy DE; Moran TM
J Immunol; 1998 Feb; 160(4):1841-9. PubMed ID: 9469445
[TBL] [Abstract][Full Text] [Related]
33. Pichinde virus-specific cell-associated suppression of primary footpad swelling in an inbred strain of Syrian hamsters.
Chan M; Clark D; Rawls WE
J Immunol; 1983 Feb; 130(2):925-31. PubMed ID: 6184408
[TBL] [Abstract][Full Text] [Related]
34. Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory.
Bründler MA; Aichele P; Bachmann M; Kitamura D; Rajewsky K; Zinkernagel RM
Eur J Immunol; 1996 Sep; 26(9):2257-62. PubMed ID: 8814275
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cells vs cytotoxic T cells in the peripheral blood of virus-infected mice.
Stitz L; Althage A; Hengartner H; Zinkernagel R
J Immunol; 1985 Jan; 134(1):598-602. PubMed ID: 2981094
[TBL] [Abstract][Full Text] [Related]
36. SV40 tumor rejection induced by vesicular stomatitis virus bearing SV40 tumor-specific transplantation antigen (SV40-TSTA). II. Association of SV40-TSTA activity with liposomes containing VSV glycolipids.
Huet C; Ansel S
Int J Cancer; 1977 Jul; 20(1):61-6. PubMed ID: 71275
[TBL] [Abstract][Full Text] [Related]
37. Development of an immunoelectroosmophoresis test for the detection and typing of antibodies to vesicular stomatitis viruses.
Wilks CR; Jenney EW; House JA
Can J Comp Med; 1984 Apr; 48(2):179-83. PubMed ID: 6326981
[TBL] [Abstract][Full Text] [Related]
38. Correlation between the lipopolysaccharide response of mice and the capacity of mouse peritoneal cells to transfer an antiviral state. Role of endogenous interferon.
Gessani S; Belardelli F; Borghi P; Boraschi D; Gresser I
J Immunol; 1987 Sep; 139(6):1991-8. PubMed ID: 3040861
[TBL] [Abstract][Full Text] [Related]
39. Generating Recombinant Vesicular Stomatitis Viruses for Use as Vaccine Platforms.
Ruedas JB; Connor JH
Methods Mol Biol; 2017; 1581():203-222. PubMed ID: 28374251
[TBL] [Abstract][Full Text] [Related]
40. Reconstitution with T lymphocytes protects nude mice from a central nervous system disorder induced by a temperature-sensitive vesicular stomatitis virus.
Doll SC; Johnson TC
J Gen Virol; 1988 Aug; 69 ( Pt 8)():1969-77. PubMed ID: 2841409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
